Open AccessAcute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea
Author(s) -
Hun Jee Choe,
Koung Jin Suh,
Ji Yun Lee,
Minyoung Kim,
Man Jin Kim,
Sung Sup Park,
Ji Won Kim,
Se Hyun Kim,
Jin Won Kim,
Jeong-Ok Lee,
Yu Jung Kim,
Moon Hyoung Lee,
Jee Hyun Kim,
Soo Mee Bang,
Jong Seok Lee
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000016318
Subject(s) - medicine , thrombophilia , factor v leiden , pulmonary embolism , asymptomatic , factor v , mutation , rivaroxaban , pediatrics , etiology , thrombosis , venous thrombosis , genetics , warfarin , gene , biology , atrial fibrillation
Rationale: Although Factor V Leiden (FVL) mutation is a major cause of inherited thrombophilia in Western populations; the mutation is extremely rare in Asia. Patient concerns: Here we report a case of a 28-year old Korean woman admitted to our hospital with extensive pulmonary embolism. Diagnosis: She was heterozygous for FVL mutation up on evaluation, and screening for asymptomatic family members also revealed heterozygous FVL mutation for her mother. Interventions: Enoxaparin 1 mg/kg was initiated, followed by rivaroxaban 15 mg every 12 hours. Outcomes: The patient showed improvement in both subjective dyspnea and right ventricular dysfunction and was successfully discharged after five hospital days. Lessons: FVL mutation screening may be considered in Asian patients with thrombophilia of uncertain etiology in the future.